Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837949 | 0.89 | BCHE (0.51) | — | |
| SCHEMBL14012818 | 0.89 | HRH3 (0.46) | S1PR5 | |
| SCHEMBL883999 | 0.89 | SMN1; SMN2 (0.44) | S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL1361484 | 0.85 | S1PR4 (0.43) | S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL1362669 | 0.84 | S1PR1 (0.40) | S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL13766174 | 0.84 | S1PR5 (0.56) | S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL14554075 | 0.84 | S1PR5 (0.56) | S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL883997 | 0.81 | SMN1; SMN2 (0.44) | S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL22322130 | 0.81 | ARG1 (0.44) | S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL3264345 | 0.80 | CYP1A2 (0.46) | S1PR4S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133179-B2 | 2-methoxy-pyridin-4-yl-derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-09-15 | — | — | US | claimed |
| EP-2665720-B1 | 2-METHOXY-PYRIDIN-4-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-06-10 | — | — | EP | claimed |
| EP-2665720-A1 | 2-METHOXY-PYRIDIN-4-YL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2013-11-27 | — | — | EP | claimed |
| US-20130303514-A1 | 2-METHOXY-PYRIDIN-4-YL-DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-14 | — | — | US | claimed |
| WO-2012098505-A1 | 2-METHOXY-PYRIDIN-4-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-07-26 | — | — | WO | claimed |
| US-8067419-B2 | N-[(S)-1-benzyl-2-(4-benzyl-piperazin-1-yl)-2-oxo-ethyl]-N-(4-pentyl-benzyl)-3-(4-trifluoromethyl-phenyl)-acrylamide, for example; antiprotozoa agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-29 | — | — | US | claimed |
| US-8039644-B2 | Hydrogenated benzo (C) thiophene derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-18 | — | — | US | claimed |
| EP-1863475-B1 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-09-07 | — | — | EP | claimed |
| US-7951794-B2 | Thiophene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-31 | — | — | US | claimed |
| EP-1863787-B1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-05-25 | — | — | EP | claimed |
| EP-1940814-A1 | PIPERAZINE DERIVATIVES AS ANTIMALARIAL AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-07-09 | — | — | EP | claimed |
| EP-1896446-A1 | NOVEL THIOPHENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-12 | — | — | EP | claimed |
| EP-1863475-A2 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | claimed |
| EP-1863474-A1 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | claimed |
| EP-1863787-A1 | HYDOGRENATED BENZO[C]THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-12-12 | — | — | EP | claimed |
| WO-2007046075-A1 | PIPERAZINE DERIVATIVES AS ANTIMALARIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-04-26 | — | — | WO | claimed |
| WO-2006137019-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-12-28 | — | — | WO | claimed |
| WO-2006100631-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | claimed |
| WO-2006100633-A1 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | claimed |
| WO-2006100635-A2 | NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-1-PHOSPHATE-1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303514-A1 | 2-METHOXY-PYRIDIN-4-YL-DERIVATIVES | CD4, IL2, IL4 | S1PR4 97/4885S1PR1 121/4885S1PR3 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.